RPS3

Small ribosomal subunit protein uS3 · P23396 · RPS3 on Sugi Atlas →

3,676 patent compounds predicted against RPS3, 1,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Proteome-based Personalized Immunotherapy of Glioblastoma	PHASE2/PHASE3	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Natural History and Genetic Studies of Usher Syndrome	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPS3 binder may also engage these)

Protein	Name	Similarity
Q0Z8U2	—	1.000	Q0Z8U2 →
Q3T169	—	1.000	Q3T169 →
G1TNM3	—	1.000	G1TNM3 →
P62908	—	1.000	P62908 →
E2RH47	—	1.000	E2RH47 →
P02350	—	1.000	P02350 →
P79891	—	1.000	P79891 →
P62909	—	1.000	P62909 →
P05750	—	1.000	P05750 →
Q5R465	—	1.000	Q5R465 →
O60128	—	0.999	O60128 →
Q9M339	—	0.999	Q9M339 →
P47835	—	0.998	P47835 →
Q90YS2	—	0.998	Q90YS2 →
Q9SIP7	—	0.997	Q9SIP7 →
P48153	—	0.997	P48153 →
Q9FJA6	—	0.996	Q9FJA6 →
A0A1D8PSV5	—	0.994	A0A1D8PSV5 →
P90526	—	0.993	P90526 →
P48152	—	0.992	P48152 →
A4YCX2	—	0.992	A4YCX2 →
Q06559	—	0.992	Q06559 →
Q9HIR5	—	0.991	Q9HIR5 →
B6YQ79	—	0.990	B6YQ79 →
Q8SQM3	—	0.990	Q8SQM3 →
B4SBV3	—	0.989	B4SBV3 →
P41119	—	0.989	P41119 →
Q12ZU5	—	0.988	Q12ZU5 →
A0RVX9	—	0.988	A0RVX9 →
B2UMT3	—	0.988	B2UMT3 →